Focal Treatment for Prostate Cancer (TULSA / TULSA‑Pro and Irreversible Electroporation)
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Governance of prior authorization and medical necessity determinations for focal therapies (TULSA/TULSA‑Pro and irreversible electroporation) for individuals enrolled in Connecticut's HUSKY Health programs; intended for CMAP providers requesting coverage.
No material clinical or coverage changes in this revision.
Coverage Determinations
TULSA / TULSA-Pro — Not Medically Necessary
TULSA and TULSA-Pro
Irreversible Electroporation — Not Medically Necessary
Irreversible Electroporation (IRE)
This policy governs coverage determinations for focal therapies used to treat localized prostate cancer. Requests for focal treatment procedures will be evaluated for medical necessity and prior authorization when applicable. TULSA / TULSA‑Pro (CPT 55881, 55882) and Irreversible Electroporation (CPT 55877) are each designated as investigational and not medically necessary for treatment of localized prostate cancer due to insufficient evidence of efficacy and safety in peer‑reviewed published literature.
TULSA / TULSA‑Pro (CPT 55881, CPT 55882) and Irreversible Electroporation (CPT 55877) are explicitly designated as investigational and not medically necessary for localized prostate cancer. Prior authorization is required for focal treatment requests and will be reviewed for medical necessity; providers should expect that requests for these CPT codes may be denied on the basis that the therapies are investigational.
Procedure and Billing Codes
| 55877 | Ablation, irreversible electroporation, prostate, 1 or more tumors, including imaging guidance, percutaneous. |
| 55881 | Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation (more than one physician). |
| 55882 | Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed (one physician). |
| 51721 | Insertion of transducer through urethra for delivery of heat ultrasound. |
Provider Requirements and Prior Authorization
Obtain prior authorization for focal treatment requests
Prior authorization is required for requests for focal treatment for prostate cancer and will be reviewed using the procedures in place for surgical prior authorization; coverage determinations are based on submitted case-specific information. Note: CPT 51721 (insertion of transducer through urethra for delivery of heat ultrasound) is listed in coding but is not exempted from review language in the source — providers must obtain prior authorization for focal treatment codes 55877, 55881, and 55882.
Provide full case-specific clinical information with the request
Submit all case-specific clinical information necessary for review as part of the prior authorization request. Documentation must support medical necessity consistent with the Connecticut statutory definition of medical necessity.
- Include clinical rationale, diagnostic findings, prior treatments, and any relevant imaging or pathology that justify the requested focal therapy.
- Ensure documentation addresses Connecticut's definition of medical necessity (Conn. Gen. Stat. § 17b-259b) referenced in the policy.
Attach documentation that supports medical necessity for review
When submitting a prior authorization for focal treatment, include documentation supporting medical necessity per the policy; reviewers will base coverage decisions on the requested and/or submitted case-specific information.
- Follow the procedures in place for reviewing surgical prior authorization requests.
- Attach relevant clinical records, imaging, pathology, and prior treatment summaries to support the request.
Requests for TULSA/TULSA‑Pro and IRE may be denied as investigational
Requests for TULSA/TULSA-Pro (CPT 55881, 55882) and Irreversible Electroporation (CPT 55877) for localized prostate cancer are considered investigational and therefore not medically necessary; such requests risk denial.
- Anticipate denial if requesting coverage for TULSA/TULSA-Pro or IRE for localized prostate cancer because the policy designates these procedures investigational.
- Consider alternative, evidence-based treatments and document why alternatives are inadequate if pursuing an exception.
Key Definitions
Clinical Background
Prostate cancer is characterized by uncontrolled growth of cells in the prostate gland and is managed with a range of options chosen according to tumor characteristics and patient goals. Two focal ablation techniques referenced in this policy are: TULSA / TULSA‑Pro, which uses transurethral MRI‑guided thermal ultrasound to ablate prostate tissue (procedures described by CPT 55881 and 55882), and Irreversible Electroporation (IRE), a minimally invasive electrical pulse–based ablation technique (CPT 55877). Both modalities currently lack sufficient peer‑reviewed evidence demonstrating clinical efficacy and safety for localized prostate cancer and therefore are not covered.
Document History
Policy originally published May 2026 and approved at the CHNCT Medical Reviewer meeting on May 13, 2026.
Approved by the CHNCT Clinical Quality Subcommittee on June 17, 2026.
Approved by the Department of Social Services (DSS) on July 2, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.